Korean gov. to introduce preferential drug pricing criteria
By Lee, Jeong-Hwan | translator Kim, Jung-Ju
24.02.06 05:50:55
가나다라
0
The 2nd NHI plan includes a revision of the post-management system, “Pharmaceutical companies contributing to the Korean economy will receive preferential drug pricing regardless of their innovative company status.”
Discussion with a public-private consultative body announced…In terms of generic drugs, the government will revise the drug pricing system and the post-management of drug pricing reduction.
▲Director Chang-Hyun Oh explained the pharmaceutical policy directions in the 2nd comprehensive National Health Insurance plan.
By the first half of this year, the government plans to establish a detailed criteria for ‘National Economic Growth,’ including the research and development (R&D) of new drugs and incrementally modified drugs, essential drugs supply, and new job creations, which will be the basis for preferential drug pricing intended for pharmaceutical companies in Korea.
The criteria will be used to implement a new policy aimed at enhancing preferential drug pricing benefits for pharmaceutical companies that have contributed to Korea’s economic growth.
The government has promised to strengthen drug pricing support using the National Health Insurance finance if a pharmaceutical company shows
Lee, Jeong-Hwan(junghwanss@dailypharm.com)
If you want to see the full article, please JOIN US (click)